COVID-19 RELATED KIDNEY DAMAGE

January 11, 2021 updated by: Aki̇f Şahi̇n, Kocaeli Derince Education and Research Hospital

INVESTIGATION OF RISK FACTORS RELATED TO COVID-19 RELATED KIDNEY DAMAGE: A PROSPECTIVE OBSERVATIONAL STUDY

In this study, we investigate whether the early detection of risk factors in Covid-19 associated acute kidney injury contributes to us in the early initiation of treatment. We predict that if acute kidney damage is detected early in patients with early risk factors, permanent kidney damage will be seen less. In addition, we think that covid-19 patients may have positive contributions to shortening treatment time and reducing treatment costs. In addition, we are investigating whether it has a positive effect on patients' survival. In other words, we are investigating the contribution of risk factors to early diagnosis and treatment, the effect on health expenditures and mortality in patients with COVID-19 with acute kidney damage.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Over 18 aged

  • patients in ICU

Description

Inclusion Criteria:

  • Over 18 aged
  • patients in ICU

Exclusion Criteria:

  • Patients with known Chronic Renal Failure
  • who have received dialysis treatment before
  • who are under 18 years of age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE
Other: ACUTE KIDNEY INJURY
KDIGO LEVELS
COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE
Other: ACUTE KIDNEY INJURY
KDIGO LEVELS
COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.
Other: ACUTE KIDNEY INJURY
KDIGO LEVELS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
KDIGO
Time Frame: 4 MONTHS
Kidney Disease: Improving Global Outcomes
4 MONTHS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kocaeli Derince Education and Research Hospital

Investigators

  • Principal Investigator: akif şahin, kocaeli derh

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

January 1, 2021

Primary Completion (Anticipated)

May 1, 2021

Study Completion (Anticipated)

May 15, 2021

Study Registration Dates

First Submitted

January 11, 2021

First Submitted That Met QC Criteria

January 11, 2021

First Posted (Actual)

January 12, 2021

Study Record Updates

Last Update Posted (Actual)

January 12, 2021

Last Update Submitted That Met QC Criteria

January 11, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • kocaeli derh

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Kidney Injury

Clinical Trials on ACUTE KIDNEY INJURY

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe